Crowdonomics
All companies
KALIA HEALTH logo

KALIA HEALTH

Operating

Kalia Health, Inc

Healthcare · Technology · Chapel Hill, NC · Founded 2018

Bringing healthcare home

Post-money valuation
$9.1M
As of Oct 2024 · from Kalia Health Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$132,698
Across 1 round since 2024
Latest share price
$0.91
Kalia Health Common Stock 1 offering price

Financials

FY2022–FY2023 · from SEC filings · hover any figure for its source
$0
−$180K
2022
$0
−$555K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$179,970
-$555,125
Taxes paid
$0
$40,151
Balance sheet
Cash
$406,324
$1,001
Accounts receivable
$300
$300
Total assets
$406,624
$1,301
Short-term debt
$0
$149,772
Long-term debt
$0
$0
Total liabilities
$0
$149,772
Other
Headcount
3

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$9.1M
post-money
Kalia Health Common Stock 1

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Kalia Health Common Stock 1ClosedReg CF · Common Equity · via StartEngine
Raised $132.7K / $1.2MInvestors 18Post-money $9.1M

Team

4 people
Denali Dahl, PhD
Chief Executive Officer, Co-Founder, & Director

Denali is a biomedical engineer and global health researcher specializing in female sexual and reproductive health. She holds degrees from UC San Diego, Duke University, and UNC Chapel Hill & NC State University. Her work includes developing a portable diagnostic tool for cervical cancer and long-acting drug delivery systems for sexually transmitted diseases and contraception.

Happy Ghosh
Chief Product Officer, Co-Founder & Director

Happy is a biomedical engineer and global health researcher with degrees from Boston University and Duke University. She has developed and evaluated medical devices for low-resource settings, including mHealth platforms, lateral flow technology for brain injury, and ultrasound coupling media. Suvomita Happy Ghosh will be providing Form C sign-off as the Company's Principal Accounting Officer.

Jamison Sexton
Chief Business Officer & Director

Jamison is an award-winning healthcare executive with over 15 years of experience in innovation and business strategy. He has worked with the Alzheimer Institute of America and Roche Diagnostics, managing commercial activities across 20 countries. Jamison excels in performance management and has a vast international network of key stakeholders.

Simon Bentley
Director

Simon Bentley is a British born entreprenuer. In 2010 he relocated from UK to the UAE. In 2015 he started Gander.ae - a production company - in the UAE. In 2018 Simon turned his attention to the Real Estate market and began purchasing properties in Dubai, UAE to leverage it's growth potential and favorable banking terms. During Covid-19 he significantly increased his porfolio in Dubai. In 2023 Simon began offloading the real estate at and average of +500% gains and divesting the returns in to other industries.

Names and titles as disclosed on StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 0 of 2 annual reports (FY2024–FY2025)

18 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-TRApr 28, 20260002042399-26-000001
    EDGAR
  • Form C-UMay 12, 20250001665160-25-001063
    EDGAR
  • Form C/AFeb 14, 20250001665160-25-000263
    EDGAR
  • Form C/AJan 29, 20250001665160-25-000155
    EDGAR
  • Form C-UDec 27, 20240001665160-24-001902
    EDGAR
  • Form COct 31, 20240001665160-24-001510
    EDGAR
Source: ManualCIK 0002042399DEShare price $0.91

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.